These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16490286)

  • 1. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms.
    Nilselid AM; Davidsson P; Nägga K; Andreasen N; Fredman P; Blennow K
    Neurochem Int; 2006 Jun; 48(8):718-28. PubMed ID: 16490286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
    Iqbal K; Flory M; Khatoon S; Soininen H; Pirttila T; Lehtovirta M; Alafuzoff I; Blennow K; Andreasen N; Vanmechelen E; Grundke-Iqbal I
    Ann Neurol; 2005 Nov; 58(5):748-57. PubMed ID: 16247771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
    Skogseth R; Mulugeta E; Jones E; Ballard C; Rongve A; Nore S; Alves G; Aarsland D
    Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease.
    van Gool WA; Kuiper MA; Walstra GJ; Wolters EC; Bolhuis PA
    Ann Neurol; 1995 Feb; 37(2):277-9. PubMed ID: 7847870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of clusterin in paired cerebrospinal fluid and plasma samples.
    Jongbloed W; Herrebout MA; Blankenstein MA; Veerhuis R
    Ann Clin Biochem; 2014 Sep; 51(Pt 5):557-67. PubMed ID: 24146185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease.
    Taniguchi M; Okayama Y; Hashimoto Y; Kitaura M; Jimbo D; Wakutani Y; Wada-Isoe K; Nakashima K; Akatsu H; Furukawa K; Arai H; Urakami K
    Dement Geriatr Cogn Disord; 2008; 26(2):117-22. PubMed ID: 18654083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders.
    Shafaati M; Solomon A; Kivipelto M; Björkhem I; Leoni V
    Neurosci Lett; 2007 Sep; 425(2):78-82. PubMed ID: 17822846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.
    Ahmed N; Ahmed U; Thornalley PJ; Hager K; Fleischer G; Münch G
    J Neurochem; 2005 Jan; 92(2):255-63. PubMed ID: 15663474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput quantification of Alzheimer's disease pathological markers in the post-mortem human brain.
    Byrne UT; Ross JM; Faull RL; Dragunow M
    J Neurosci Methods; 2009 Jan; 176(2):298-309. PubMed ID: 18835409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods.
    Simonsen AH; Hansson SF; Ruetschi U; McGuire J; Podust VN; Davies HA; Mehta P; Waldemar G; Zetterberg H; Andreasen N; Wallin A; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(4):246-50. PubMed ID: 17310122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF Abeta42 levels.
    Stenset V; Hofoss D; Johnsen L; Skinningsrud A; Berstad AE; Negaard A; Reinvang I; Gjerstad L; Fladby T
    Acta Neurol Scand; 2008 Dec; 118(6):373-8. PubMed ID: 18510598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-borne factors inhibit Alzheimer's beta-amyloid fibril formation in vitro.
    Ono K; Noguchi-Shinohara M; Samuraki M; Matsumoto Y; Yanase D; Iwasa K; Naiki H; Yamada M
    Exp Neurol; 2006 Nov; 202(1):125-32. PubMed ID: 16806179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
    Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
    Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells.
    Trouw LA; Nielsen HM; Minthon L; Londos E; Landberg G; Veerhuis R; Janciauskiene S; Blom AM
    Mol Immunol; 2008 Aug; 45(13):3649-60. PubMed ID: 18556068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease.
    Montine TJ; Quinn JF; Milatovic D; Silbert LC; Dang T; Sanchez S; Terry E; Roberts LJ; Kaye JA; Morrow JD
    Ann Neurol; 2002 Aug; 52(2):175-9. PubMed ID: 12210787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.